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Elastic fibres play a key role in bodily functions where fatigue resistance and elastic recovery are necessary while
regulating phenotype, proliferation and migration in cells. While in vivo elastic fibres are created at a late foetal
stage, a major obstacle in the development of engineered tissue is that human vascular smooth muscle cells
(hVSMCs), one of the principal elastogenic cells, are unable to spontaneously promote elastogenesis in vitro.
Therefore, the overall aim of this study was to activate elastogenesis in vitro by hVSMCs seeded in fibrin,
collagen, glycosaminoglycan (FCG) scaffolds, following the addition of recombinant human tropoelastin. This
combination of scaffold, tropoelastin and cells induced the deposition of elastin and formation of lamellar
maturing elastic fibres, similar to those found in skin, blood vessels and heart valves. Furthermore, higher
numbers of maturing branched elastic fibres were synthesised when a higher cell density was used and by droploading tropoelastin onto cell-seeded FCG scaffolds prior to adding growth medium. The addition of tropoelastin
showed no effect on cell proliferation or mechanical properties of the scaffold which remained dimensionally
stable throughout. With these results, we have established a natural biomaterial scaffold that can undergo
controlled elastogenesis on demand, suitable for tissue engineering applications.

1. Introduction
Fatigue resistance and elastic recovery are critically important me
chanical properties for the correct functioning of the heart, skin, lungs
and other dynamic connective tissues within the human body. Elastic
fibres play a key role in bodily functions where these mechanical
properties are necessary [1]. Indeed, elastin is one of the most abundant
proteins found in vertebrates, providing resistance to permanent tissue
deformation [2] and delivering biochemical cues that regulate cell
migration, preventing proliferative diseases in heart and blood vessels
[3,4]. In a mature elastic fibre, approximately 90% of the volume is
composed of elastin that is surrounded by a fibrillin-rich microfibrillar
mesh [5]. However, the content, alignment and morphology of these
mature elastic fibres is dictated by functional demands and the cells that

deposit and orientate the fibrillin-rich microfibrils. For instance, elastic
ligaments have approximately 50% elastin content [6] with elastic fibres
that resemble rope-like networks giving joints stability and flexibility.
Blood vessels have a 30% elastin content, and the elastic fibres can be
observed as concentric fenestrated lamellae required for stress propa
gation during each cardiac cycle. Having 15% of elastin content, heart
valves show a mixed architecture of elastic fibres; while the ventricularis
layer of the leaflets has elastic fibres aligned radially to withstand the
blood inflow [7], reticular elastic fibres are present throughout the heart
valve to reduce permanent deformation [8]. Lungs on the other hand
(3–7% elastin), present elastic fibres that are highly branched along the
respiratory tree and facilitate alveoli expansion. Finally, skin, which
contains approximately 2% of elastin [9], has elastic fibres that are thick
and horizontally arranged in the dermis, whereas in the papillary
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dermis, these fibres are perpendicularly oriented [10]. While many
biocompatible materials have been developed for tissue engineering
applications, to date they are unable to fully mimic the function of native
tissue, as they do not encourage the production of new elastic fibres
through elastogenesis [11].
Elastogenesis is a hierarchical elastic fibre assembly process that is
highly upregulated at late foetal and neonatal stage [12]. Tropoelastin,
the soluble precursor of elastin, is essential for the assembly of elastic
fibres [6]. In a normal elastogenesis process, cells produce tropoelastin
that is chaperoned by elastin-binding proteins (EBP) to prevent prema
ture coacervation into elastin [13]. When tropoelastin leaves the cellular
membrane, it coacervates into elastin chains within the extracellular
matrix (ECM). Elastin then begins to crosslink using lysyl oxidase
(LOX1), copper, fibulin 4 and 5 to make insoluble elastin that is finally
deposited in the microfibrillar mesh [12], allowing elastic fibres to form
with a lifespan of approximately 70 years [14,15]. From the estimated
200 cell types found in the human body [16], only smooth muscle cells,
fibroblasts, endothelial cells, chondroblasts and mesothelial cells are
capable of assembling elastic fibres in vivo [17]. However, a major issue
for researchers is that these cells are unable to spontaneously undergo
elastogenesis in vitro.
Indeed, much research in recent years has focused on finding ways to
induce elastogenesis in cell culture using exogenous agents [18]. In vitro,
glycosaminoglycans (GAGs) such as heparin [19], hormones, growth
factors [20–23] and gene expression therapy [24] can induce production
of tropoelastin in cells and upregulation of microfibrillar associated
genes, leading to the formation of elastic fibres in fibroblasts and smooth
muscle cells (SMCs). Another way of obtaining elastic fibres in vitro is by
adding a solution of recombinant human tropoelastin that can be
incorporated into the ECM, thereby skipping the tropoelastin synthesis
phase inside the cell [12,17,25,26]. Additionally, it has been welldocumented that similarly to natural tropoelastin, recombinant human
tropoelastin can modulate the assembly of elastic fibres in the ECM,
while promoting attachment of cells and regulating their proliferation
[1,27–30]. Recently, Mithieux et al. presented ways of obtaining elastic
fibres in silicone and collagen constructs. This was achieved through
repeated additions of recombinant synthetic human tropoelastin and
conditioned growth medium, using dermal fibroblasts of different age
groups [31]. As a result of these findings, there is a need to examine
whether this technique can be translated into other cell-seeded bioma
terial constructs. Additionally, the effect of the method and timing of
recombinant human tropoelastin addition, on the deposition of elastic
fibres, warrants examination.
Our research group is specialised in the fabrication of natural poly
mer based porous scaffolds, for several medical applications including
cartilage [32,33], bone [34], nerve [35], and vascular [36] repair. We
have developed a platform for soft tissue engineering that can resist cellmediated contraction using fibrin gels reinforced with a freeze-dried
collagen-glycosaminoglycan matrix [37]. Although these fibrincollagen-glycosaminoglycan (FCG) scaffolds have proven to be dimen
sionally stable in cell culture when seeded with smooth muscle cells, the
next step is to develop a repeatable method to increase and tune the
content of elastic fibres when cultured with appropriate cells. This
milestone will take us a step closer to meeting the unmet need of a fully
functional natural biomaterial scaffold, able to undergo elastogenesis on
demand, with increased elastic recoil and fatigue life. Such a biomaterial
may prove suitable for a variety of applications.
Therefore, the overall aim of this study was to activate elastogenesis
by human vascular smooth muscle cells (hVSMCs) seeded in the FCG
scaffolds. We established the influence of the timing of tropoelastin
addition on the maturing elastic fibre deposition, cell proliferation and
gene expression of hVSMCs seeded on glass slides. Next, we assessed the
effect of changing the method of addition of tropoelastin on the depo
sition and area coverage of elastin and maturing elastic fibres in FCG
scaffolds seeded with hVSMCs. Finally, we studied the effect of
controlled elastogenesis on the cell proliferation, mechanical and

dimensional properties and elastogenesis associated gene expression in
FCG scaffolds seeded with hVSMCs.
2. Materials and methods
2.1. Cell culture
A human vascular smooth muscle cell line (hVSMC) from an 11month female Caucasian (CRL-1999, ATCC, Middlesex, UK), was
cultured in growth medium composed of F-12K Medium (ATCC), with
added 50 μg/ml ascorbic acid, 16 μl/ml Insulin, Transferrin, Selenium
(ITS, Sigma-Aldrich), 30 μg/ml Endothelial Cell Growth Supplement
(ECGS, Sigma-Aldrich), 10% foetal bovine serum, 1% penicillin/strep
tomycin, 10 mM, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES, Sigma-Aldrich) and 10 mM 2-[(2-Hydroxy-1,1-bis(hydroxy
methyl)ethyl)amino]ethanesulfonic
acid,
N-[Tris(hydroxymethyl)
methyl]-2-aminoethanesulfonic acid (TES, Sigma-Aldrich). Growth
medium was replaced every three days and cells sub-cultured, once fully
confluent, using 0.25% trypsin 0.53 mM EDTA solution (Sigma-Aldrich).
2.2. Tropoelastin solution preparation
For these experiments, recombinant synthetic human tropoelastin
without hydrophilic domain 26A (SHELΔ26A) (amino acid residues
27–724 of GenBank entry AAC98394). The production process involved
overexpression of tropoelastin in Escherichia coli followed by purifica
tion and this has been previously described [38,39]. The resultant
lyophilised tropoelastin was dissolved overnight in phosphate buffer
saline (PBS, Sigma-Aldrich), to obtain a 10 mg/ml solution.
2.3. 2D elastogenesis model
To assess the optimal timing of tropoelastin addition in order to
enhance the deposition of more elastic fibres, two groups were studied.
Samples were treated with tropoelastin on day 0 (A0) and further
samples were treated on day 10 (A10), as the rationale in this model is
that a mature ECM would enhance the deposition of elastin and
maturing elastic fibres. Therefore, hVSMCs were seeded in 12-well
plates containing glass cover slips at a density of approximately
50,000 cells per well. 50 μl of 10 mg/ml tropoelastin was added to all the
samples on their designated day. After adding growth medium, the final
concentration of tropoelastin per well was 250 μg/ml. Growth medium
changes were carried out on days 3 and 5 of the experiment. Samples
were collected on days 1, 3 and 7 post-tropoelastin addition for cell
number quantification, real-time quantitative PCR (RT-qPCR), immu
nofluorescence (anti-elastin) and maturing elastic fibre auto
fluorescence at 561 nm [31].
2.4. Elastin and elastic fibre area coverage estimation
Immunofluorescence was carried out to visually assess for the pres
ence of elastin and maturing elastic fibres. Samples were fixated with
10% formalin for 15 min, washed twice in PBS and three times with 0.2
M Glycine (Sigma-Aldrich). Samples were incubated for 1 h at 37 ◦ C in
5% w/v bovine serum albumin (Sigma-Aldrich), kept in the fridge
overnight with 1:100 BA4 anti-elastin antibody (Abcam, Cambridge,
UK), incubated with 1:500 Alexa Fluor® 488 (Abcam) for 1 h at 37 ◦ C.
Glass microscope slides and Fluoroshield with DAPI (Sigma-Aldrich)
were used to mount the 2D samples while 3D samples were kept in
glycine. Elastin was observed at 488 nm (green channel) and maturing
elastic fibres (covalently cross-linked elastin) were visualised at a
wavelength of 561 nm (red channel) using a confocal microscope, due to
its autofluorescence. The following calculations were carried out using
the image processing package, Fiji [40]. Relative area coverage was
carried out by thresholding the elastin and maturing elastic fibres
channels and quantifying the intensity of each pixel (n = 4). Maturing
2
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elastic fibre alignment was assessed by smoothing the respective chan
nel and analysing it using the directionality function, which estimates
the preferred orientation of clusters of pixels in the image using the
Fourier spectrum analysis method.

from the wells and used two methods to add tropoelastin to the FCG
scaffolds: 1) drop-loading 50 μl of 10 mg/ml tropoelastin onto the
scaffolds, waiting 10 min before adding fresh growth medium and 2)
adding growth medium which already contained 50 μl of 10 mg/ml of
tropoelastin. In both cases, the final concentration of tropoelastin per
well was 250 μg/ml. It is worth mentioning that concentration de
pendency studies were not carried out using our scaffolds, therefore the
concentration of tropoelastin chosen for this study was based on a pre
vious recombinant human tropoelastin publication [31]. Growth me
dium changes were carried out every 3 days. Seven days post initial
tropoelastin addition, a second round of tropoelastin was added onto the
FCG scaffolds using the two methods described above. Samples were
collected on days, 3, 7 and 14 (post initial tropoelastin addition) for
dsDNA quantification, RT-qPCR, immunofluorescence (anti-elastin) and
autofluorescence at 561 nm, as described in previous paragraphs (n = 3
for all assays).

2.5. Cell number quantification
To investigate the influence of tropoelastin on the proliferation of
hVSMCs, a Quant-iT PicoGreen dsDNA kit (BD BioSciences, Oxford, UK)
was used. This kit can detect double-stranded DNA (dsDNA) through
fluorescence imaging. Samples (n = 3 for each time point) were washed
in PBS and kept at − 20 ◦ C in a solution of 0.2 M NaCO3 and 1% Triton X
(Sigma-Aldrich). Each sample was diluted 25× with 1xTE Buffer,
pipetted into a 96-well plate and treated with a 200-fold PicoGreen
dilution. Using a TECAN plate reader, samples were excited at 485 nm
and read at 538 nm. dsDNA concentration was calculated by comparing
the fluorescence levels from each sample against a standard fluorescence
curve [41].

2.7.3. Quantification of elastin deposited within the FCG scaffolds
The Fastin™ Elastin Assay kit (Biocolor Ltd., Carrickfergus, UK) was
used to quantify the amount of elastin deposited in FCG scaffolds.
Briefly, FCG scaffolds (n = 4) were collected on days 3, 7 and 14, washed
3 times in PBS and weighed. For the extraction of soluble α-elastin, FCG
scaffolds were fully digested in 0.25 M oxalic acid for 1 h at 100 ◦ C.
Following elastin solubilisation, 500 μl from each sample was precipi
tated, centrifuged and mixed with dye reagent. The resultant elastin-dye
complex was centrifuged and the pellet solubilised using the dye
dissociation agent. Samples were transferred to a clear 96-well plate and
absorbance at 513 nm was measured using the plate reader. Observa
tions were normalised to the corresponding blanks (0.25 M oxalic acid)
and expressed in μg of elastin per 100 mg of wet scaffold.

2.6. Elastogenesis associated gene expression
To evaluate the influence of tropoelastin on the gene expression of
elastin (ELN), elastin-binding protein (EBP), fibrillin 1 (FBN1) and lysyl
oxidase (LOX1) genes (ELN QT00034594, EBP1 QT00087570, FBN1
QT00024507, LOX1 QT00017311, Qiagen, Manchester, UK) RT-qPCR
was carried out. Three samples per group (n = 3) at each of the time
points were washed in PBS and kept at − 20 ◦ C with Qiazol lysis reagent
(Qiagen). RNA was extracted and reverse transcription carried out with
a Quantitec Reverse Transcription kit (Qiagen). The resultant comple
mentary DNA (cDNA) samples were prepared with PCR Master Mix
(Bioline, London, UK) and analysed using an Eppendorf® Mastercycler®
ep realplex 4 with the following program: 15 min at 95 ◦ C, 15 s at 94 ◦ C,
30 s at 55 ◦ C, 45 s at 72 ◦ C (the previous three steps repeated 40 cycles),
15 s at 95 ◦ C, 15 s at 60 ◦ C, 20 min melting curve and 15 s at 95 ◦ C.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, QT00079247,
Qiagen) was used as the housekeeping gene and relative fold gene
expression of samples was calculated using the 2− ∆∆Ct method [42].

2.7.4. Mechanical characterisation of FCG scaffolds
FCG scaffolds (n = 3) soaked in PBS were compressed uniaxially,
perpendicular to their flat face, to 10% strain at 0.1% strain per second.
The compressive modulus was obtained by calculating the slope of the
stress-strain curves [47]. Dog bone-shaped FCG scaffolds (n = 3, only
day 14 samples due to cell numbers involved), as per ASTM D638, were
hydrated in PBS and tested using a tensile preload of 0.01 N at a tension
rate of 5 mm/min until failure. Tests were carried out using a universal
testing machine (Zwick/Roell) fitted with a 5 N load cell. Ultimate
tensile strength, strain to failure, low strain (2–5%) and high strain
(10–15%) tensile modulus were calculated from the stress-strain curves
generated [48]. To assess the effect of the addition of tropoelastin on the
dimensional integrity of FCG scaffolds, they (n = 3) were photographed
using a digital camera, and their diameter was measured using the image
processing package, Fiji [40].

2.7. 3D elastogenesis model
2.7.1. Fabrication of cell-seeded FCG scaffolds
To create FCG scaffolds, a collagen-GAG (CG) matrix was created and
infiltrated with fibrin. Briefly, CG scaffolds (⌀ 10 mm × 5 mm discs)
were fabricated by freeze-drying a solution of 0.05 M glacial acetic acid
containing 0.75% w/v type I bovine tendon collagen (Southern Lights
Biomaterials, New Zealand) and 0.044% w/v shark cartilage
chondroitin-6-sulfate (Sigma-Aldrich). Final freezing temperature was
set at − 10 ◦ C to create scaffolds with an average pore size of 120 μm
[43]. CG scaffolds were physically cross-linked using dehydrothermal
treatment (DHT) [44], then chemically cross-linked using 1-ethyl-3–3dimethyl aminopropyl carbodiimide (EDAC), N-hydroxysuccinimide
(NHS) (Sigma–Aldrich) and ethanol [45]. Fibrin gel components were
fabricated as previously described [37]. To fabricate acellular FCG
scaffolds, tris-buffered saline (pH 7.4), 50 mM CaCl2, 40 IU/ml thrombin
(Sigma-Aldrich) and 10 mg/ml of fibrinogen, were pipetted into the
scaffolds. To fabricate cell-seeded FCG scaffolds, hVSMCs (density of
1000 cells/mm3) were mixed with 10 mg/ml of fibrinogen and added
into each scaffold. To reduce the speed of the enzymatic degradation of
fibrin, the growth medium contained 20 μg/ml of aprotinin (SigmaAldrich) [46]. We will refer to cell-seeded FCG scaffolds as FCG scaffolds
from here on.

2.8. Statistical analyses
Results are expressed as mean ± standard deviation. Two-way
analysis of variance (ANOVA) and Bonferroni post-test were carried
out to analyse dsDNA concentration, gene relative fold change, elastin
quantification, elastin coverage area, maturing elastic fibre coverage
area, compressive modulus and dimensional integrity. t-test and MannWhitney U test was carried out to assess tensile modulus results. All
results were compared against untreated samples (no tropoelastin
added) and P < 0.05 was defined as statistically significant.
3. Results
3.1. Mature ECM enhanced elastogenesis
Samples on glass slides were treated with tropoelastin on day 0 (A0)
and further samples were treated on day 10 (A10) based on the hy
pothesis that a higher density of cells may result in more ECM synthesis
and this would enhance the deposition of elastin and maturing elastic

2.7.2. Method of tropoelastin addition to FCG scaffolds
Once the cells had been proliferating in the scaffolds for 7 days, we
assessed the effect that the method of tropoelastin addition had on the
formation of elastin and elastic fibres. We removed the growth medium
3
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fibres. Indeed, elastin and maturing elastic fibre deposition was visible
on day 3 in A10 samples (Fig. 1E), with a steady and significant depo
sition of elastin (Fig. 1F, G) and maturing elastic fibres (Fig. 1J, K) on
days 7 and 14. A0 samples on the other hand, showed a small amount of
elastin on day 3, however no elastin or maturing elastic fibres were
observed at any other time point. As expected, samples with no tro
poelastin added, showed no elastin or maturing elastic fibres during the
experiment (Fig. 1A-D, H).
To quantify the elastin and maturing elastic fibres observed, mea
surements of the relative area coverage of both were carried out using
image analysis software. As expected, A10 samples had a significantly
higher content of elastin and maturing elastic fibres than A0 samples
(Fig. 2). On day 3, 13% of the surface area of the A10 samples was
covered by elastin (p < 0.001) and by day 14, this coverage increased to
almost 20% (p < 0.001). When the coverage of maturing elastic fibres
was measured on day 3, there was less than 1% coverage and by day 14
the coverage was approximately 8% (p < 0.001). In addition, assessment
of fibre alignment in A10 samples showed a preferred orientation of the
maturing elastic fibres as indicated by the directionality curves (Fig. 2C).
We have proven that a mature ECM increased significantly the deposi
tion of elastin and maturing elastic fibres in hVSMCs seeded on glass
slides.

219 ± 46 ng/ml. Within three days of treatment, dsDNA concentration
remained constant; 247 ± 0.3 ng/ml in A0 samples, 315 ± 117 ng/ml in
A10 samples and 228 ± 09 ng/ml in untreated samples. Untreated
samples showed a significantly higher dsDNA concentration (658 ± 117
ng/ml) than A0 samples (469 ± 27 ng/ml) and A10 samples (332 ± 13
ng/ml) after seven days. These results demonstrate that tropoelastin
regulates the proliferation of hVSMCs seeded on glass slides regardless
of cell density levels.
3.1.2. Tropoelastin addition triggered elastogenesis
Having assessed cell proliferation on glass slides, the next step was to
study the effect of the day of addition of tropoelastin on the expression of
the elastin (ELN), lysyl oxidase-1 (LOX1), elastin binding protein (EBP)
and fibrillin-1 (FBN1) genes in hVSMCs. One day after the addition of
tropoelastin in A0 samples, there was a slight upregulation of LOX1 (1.2
± 0.03) and EBP (1.3 ± 0.5), whereas ELN and FBN1 remained un
changed. Samples collected on day 3 presented upregulation of ELN (1.3
± 0.7), LOX1 (1.5 ± 0.5) EBP (1.3 ± 0.2) and FBN1 (1.4 ± 0.4) (Fig. 4A,
B, D). Downregulation of ELN, LOX1 and FBN1 occurred on day 7,
however EBP (1.3 ± 0.1) remained upregulated.
On the other hand, in A10 samples on day 1, there was down
regulation of ELN (0.3 ± 0.3), LOX1 (0.5 ± 0.1), EBP (0.8 ± 0.6) and
FBN1 (0.6 ± 0.3). Three days later upregulation of FBN1 (1.3 ± 2)
occurred. We could see that on days 3 and 7, ELN and LOX remained
downregulated. Furthermore, a relative fold change of 1.7 ± 1 in FBN1
and a 3-fold increase in EBP (p < 0.001) was observed after seven days
(Fig. 4C). As there is no significant production of elastin or associated
proteins (except EBP in A10 samples) by cells, we have demonstrated
that elastogenesis was induced solely by adding tropoelastin on
hVSMCs.

3.1.1. Tropoelastin regulated cell proliferation
The effect of tropoelastin on the proliferation of hVSMCs was
measured using a PicoGreen assay over a 1-week period. Untreated
samples presented a higher cell proliferation rate (p < 0.001) when
compared to A0 and A10 samples (Fig. 3). On day 1, A0 samples and A10
samples had a mean dsDNA concentration of 242 ± 53 ng/ml and 297 ±
36 ng/ml respectively, while the untreated samples were measured at

Fig. 1. Immunofluorescence of elastin (green) and autofluorescence at 561 nm of maturing elastic fibres (red) in hVSMCs treated with tropoelastin on A0 and A10
samples. A0 samples (A, B, C) did not show elastin or maturing elastic fibres. In contrast, both elastin (E, F, G) and maturing elastic fibres (I, J, K) were observed in
A10 samples on days 3, 7 and 14. (D, H) Untreated samples imaged on day 14. (L) Sample treated with tropoelastin without primary antibody (negative control).
White arrows represent lamellar-like elastic fibres. Blue = cell nuclei stained with DAPI. Scale bar represents 100 μm in all images. (For interpretation of the ref
erences to colour in this figure legend, the reader is referred to the web version of this article.)
4
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dsDNA concentration (ng/ml)

Fig. 2. Relative area coverage of elastin and maturing elastic fibres in A0 and A10 samples. There was a steady increase in (A) elastin and (B) maturing elastic fibre
coverage in A10 samples at all time points. There was no evidence of elastin or maturing elastic fibres in A0 samples. (C) Directionality curves of maturing elastic
fibres in A10 samples. Curves show a preferred orientation of maturing elastic fibres. (***) p < 0.001 when compared to A0 samples at the same time point. (^^^) p <
0.001 when compared to untreated samples.

1000
800

A0 samples
A10 samples
Untreated

increase in the overall content of elastin deposited in FCG scaffolds,
therefore at the end of the experiment, the amount of tropoelastin was
approximately 172.3 ± 37 μg in drop-loaded samples and 167.1 ± 28 μg
in the media-loaded samples. Although there was a modest 10%
reduction in elastin concentration per week, this drop in elastin was not
significant. In contrast, significantly higher amounts of elastin were
deposited in the groups treated with tropoelastin (p < 0.001) when
compared against untreated samples (Fig. 5). These results demonstrate
that tropoelastin can be deposited into cell-seeded FCG scaffolds and
maintained without substantial losses.

^^^

600
400
200

3.2.1. Drop-loading tropoelastin improved the surface area coverage of
maturing elastic fibres in FCG scaffolds
After quantifying the deposition of tropoelastin in FCG scaffolds as a
function of the method of addition, we followed with the visual
assessment of the surface area coverage of elastin and maturing elastic
fibres in these scaffolds. Although the amount of elastin and maturing
elastic fibres looked similar in drop-loaded and media-loaded samples
(Fig. 6), there was a 4-fold increase in elastin (p < 0.001) and a 2-fold
increase in maturing elastic fibre surface coverage (p < 0.001) in
drop-loaded samples by day 14 (p < 0.001). Three days after the addi
tion of tropoelastin, elastin was strikingly visible in both drop-loaded
(Fig. 6A) and media-loaded (Fig. 6E) samples, appearing in both as
elastin globules. However, by day 7 an unexpected decrease in this
elastin content was observed (Fig. 6B, F). Interestingly, by day 14,
maturing elastic fibres were visible in drop-loaded and media-loaded
samples (Fig. 6B, F). At each time point cells were evenly distributed
and not clumped. Acellular samples (Fig. 6H) and samples free from
tropoelastin (Fig. 6D), did not present elastin or maturing elastic fibres.
Relative area coverage of elastin and maturing elastic fibres was
quantified on the surface of the scaffolds, being significantly higher in
the drop-loaded samples by the end of the experiment. Elastin coverage
significantly increased in both drop-loaded (30 ± 9%) and media-loaded
(24 ± 7%) samples on day 3 (p < 0.001), as can be seen in Fig. 7A. Day 7,

0
Day 1

Day 3

Day 7

Fig. 3. Cell proliferation of hVSMCs seeded on glass slides treated with tro
poelastin. dsDNA concentration slowly increased in A0, A10 and untreated
samples. There was no difference between untreated and treated samples on
days 1 and 3. On day 7 dsDNA concentration was significantly higher in un
treated samples than A0 and A10 samples. (^^^) p < 0.001 when compared to A0
and A10 samples at the same time point.

3.2. Enhanced elastin deposition in FCG scaffold groups treated with
tropoelastin
Having shown that higher density of cells resulted in a higher
deposition of maturing elastic fibres (Fig. 2), we used this result when
designing our 3D studies where we examined the effect of the method of
addition of tropoelastin. The deposition of tropoelastin in FCG scaffolds
was quantified using the Fastin™ Elastin Assay kit. On day 3, droploaded samples presented 223.5 ± 31 μg and media-loaded 224.2 ±
16 μg of elastin deposited per 100 mg of wet scaffold. Seven days after
the initial addition of tropoelastin, there was approximately 194.4 ± 36
μg and 202 ± 31 μg in drop-loaded and media-loaded samples respec
tively. After the second addition of tropoelastin, there was no tangible
5
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µg elastin/100 mg wet scaffold

Fig. 4. Relative gene expression of ELN, LOX1, EBP and FBN1 in A0 and A10 samples. There was significant downregulation of (A) ELN and (B) LOX1 in A10 samples
on days 1, 3 and 7. A 3-fold increase in (C) EBP expression in A10 samples was observed on day 7. There were no significant changes in (D) FBN1 expression. (^) p <
0.05, (^^) p < 0.01, (^^^) p < 0.001 when compared to untreated samples. (*) p < 0.05, (**) p < 0.01, (***) p < 0.001 when compared to A0 samples at the same
time point.

samples (0.8 ± 1%) by day 14 (Fig. 7B). Comparing addition methods,
the drop-loaded samples presented a higher coverage of elastin (p <
0.001) and maturing elastic fibres (p < 0.001) than the media-loaded
samples on day 14. Additionally, after assessing the maturing elastic
fibre alignment both groups treated with tropoelastin presented a
disordered fibre arrangement as the directionality curves were relatively
flat (Fig. 7C, D), if compared with the curves from the 2D elastogenesis
model (Fig. 2C). With these results we can state that drop-loading tro
poelastin directly onto cell-seeded FCG scaffolds before adding cell
growth medium resulted in a better coverage of elastin and maturing
elastic fibres on the scaffold surface.

Tropoelastin Drop-loaded
Tropoelastin Media-loaded
Untreated
300

^^^ ^^^

250

^^^ ^^^

^^^ ^^^

200
150
100

3.2.2. Consistent cell proliferation in FCG scaffolds treated with
tropoelastin
Having shown that drop-loading tropoelastin resulted in a better
superficial distribution of elastin and maturing elastic fibres, cell pro
liferation, gene expression and mechanical testing assays were carried
out only on drop-loaded samples. When measured, the rate of cell pro
liferation proved to be constant between untreated samples and those
treated with tropoelastin, across all time points (Fig. 8). Three days after
the addition of tropoelastin, the average dsDNA concentration was 175
± 10 ng/ml for the untreated samples and 213 ± 8 ng/ml for the
tropoelastin-treated samples. Untreated samples had a mean dsDNA
concentration of 225 ± 10 ng/ml and the tropoelastin-treated samples
192 ± 20 ng/ml by day 7. After 14 days, the concentration of dsDNA
remained consistent in both untreated (198 ± 15 ng/ml) and
tropoelastin-treated (186 ± 26 ng/ml) groups.

50
0
Day 3

Day 7

Day 14

Fig. 5. Quantification of elastin deposited in FCG scaffolds. Drop-loaded and
media-loaded samples presented significantly higher amounts of elastin
deposited than untreated samples. (^^^) p < 0.001 when compared to un
treated samples.

on the other hand, showed a drop, to approximately 2% in the elastin
coverage area regardless of the method of addition. A second addition of
tropoelastin increased the elastin coverage by day 14 up to 3 ± 2% in
media-loaded (Fig. 7C) and 11 ± 6% (p < 0.001) in drop-loaded
(Fig. 7D) samples. On day 3, the content of maturing elastic fibres in
both methods of addition of tropoelastin was approximately 2% (droploaded 2.6 ± 0.8, media-loaded 2 ± 1.7%). This content of maturing
elastic fibres decreased to 1.2 ± 0.7% in drop-loaded and 1.7 ± 1.4% in
media-loaded samples on day 7. After the second addition of tropoe
lastin, drop-loaded and media-loaded samples treated with tropoelastin
presented a significantly higher quantity of maturing elastic fibres (12.3
± 4.5% and 5.9 ± 2.4% respectively) in comparison to untreated

3.2.3. Tropoelastin-treated FCG scaffolds showed elastin gene expression
RT-qPCR analysis presented in Fig. 9 showed that there was signifi
cant ELN upregulation (1.7 ± 0.7) on day 3. The addition of tropoelastin
resulted in upregulation of FBN1 (1.5 ± 0.6) on day 7. Overall, there was
stable upregulation of ELN and EBP on days 7 and 14. Furthermore,
LOX1 did not change at the time points studied. Therefore, similarly to
6
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Fig. 6. Immunofluorescence of elastin (green) and autofluorescence at 561 nm of maturing elastic fibres (red) in FCG scaffolds according to the method of addition of
tropoelastin. FCG scaffolds drop-loaded with tropoelastin on days (A) 3, (B) 7 and (C) 14. FCG scaffolds media-loaded with tropoelastin on day 3 (E), day 7 (F) and
day 14 (G). There was an increase in maturing elastic fibre surface coverage on day 14 after second addition of tropoelastin. (D) FCG scaffolds with no tropoelastin
added. (H) Acellular FCG scaffold treated with tropoelastin imaged on day 14. Blue = cell nuclei. Bar represents 100 μm in all images. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)

Fig. 7. Relative surface area coverage of elastin and maturing elastic fibres in FCG scaffolds. On day 14, drop-loaded and media-loaded samples presented a
significantly higher quantity of maturing elastic fibres than untreated samples. Drop-loaded samples presented significantly higher content of (A) elastin and (B)
maturing elastic fibres deposited if compared with media-loaded samples. Directionality curves of maturing elastic for (C) drop-loaded and (D) media-loaded samples
on day 14. The curves are relatively flat, as there is no preferred elastic fibre orientation. (^^) p < 0.01, (^^^) p < 0.001 when compared to untreated samples. (*) p <
0.05, (***) p < 0.001 when compared to media-loaded samples at the same time point.

the 2D studies (Fig. 4), these 3D results indicate that elastogenesis was
triggered after the addition of tropoelastin.

in Table 1, fourteen days after the addition of tropoelastin, the
compressive and tensile modulus, ultimate tensile strength (UTS) and
strain to failure of the samples treated with tropoelastin remained
comparable to those of untreated samples.
Although no significant differences were observed in the stress-strain
curves (Fig. 10A, B), in terms of compressive modulus (Fig. 10C), on day
14 the modulus of treated samples was lower (0.16 ± 0.02 kPa) than
untreated samples (0.19 ± 0.1 kPa). At low strain (2–5% strain), by day

3.2.4. No detrimental changes in mechanical properties and stable
dimensional integrity of tropoelastin-treated FCG scaffolds
Our next step was to analyse how the mechanical properties and
dimensional integrity of the FCG scaffolds were influenced by the
presence of elastin and maturing elastic fibres. Based on the data shown
7
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4. Discussion

Tropoelastin-treated
Untreated

300
250

Encouraging and controlling the production of new elastic fibres
through elastogenesis is highly desirable in regenerative medicine, as
elastic fibres prevent permanent tissue deformation while regulating
phenotype, proliferation and migration in cells [3,30]. Therefore, the
overall aim of this study was to activate elastogenesis in human vascular
smooth muscle cells (hVSMCs) seeded in fibrin collagen glycosamino
glycan (FCG) scaffolds, by adding a solution of recombinant human
tropoelastin. In this manuscript, we present a repeatable method to in
crease and tune elastogenesis by hVSMCs seeded in FCG scaffolds.
hVSMCs were chosen as they are one of the principal elastogenic cells in
the human body [49] however, hVSMCs are unable to produce elastin in
vitro as they age when their passage increases [2]. Although hVSMCs and
recombinant human tropoelastin have been previously used together in
synthetic scaffolds [50], their combined elastogenic potential has never
previously been examined. Additionally, unlike previous elastogenesis
experiments involving SMCs [28,51], we have used a natural biomate
rial scaffold and static cell culture. Here, elastogenesis was activated
after the addition of tropoelastin and furthermore, the importance of a
mature ECM to obtain enhanced deposition of elastin and maturing
elastic fibres in tropoelastin-treated hVSMCs was shown. Moreover, we
have demonstrated that the drop-loading of tropoelastin, resulted in
maturing elastic fibre surface coverage, without affecting the cell

200
150
100
50
0
Day 3

Day 7

Day 14

Fig. 8. dsDNA concentration in FCG scaffolds. No significant difference was
observed in the rate of cell proliferation between untreated samples and sam
ples treated with tropoelastin.

14 the average tensile modulus of tropoelastin-treated samples was 1.6
± 0.3 kPa, when compared to untreated samples (1.8 ± 0.4 kPa). At high
strain (10–15% strain), the modulus of the tropoelastin-treated samples
was 5.8 ± 0.1 kPa (Fig. 10D). Additionally, scaffold tensile properties
were examined with representative stress-strain curves. A small increase
in treated samples UTS (64.7 ± 8.3 kPa) and strain to failure (17.1 ±
1.3%) was observed when compared against untreated samples.
Furthermore, the standard deviations of the tropoelastin-treated sam
ples were smaller than the untreated group. Finally, cell-mediated
contraction was studied during two weeks and only a 2% decrease in
diameter was observed in the tropoelastin-treated scaffolds, which is
comparable to the untreated samples (Fig. 11A, B). These assessments
have confirmed that the addition of tropoelastin did not affect nega
tively the mechanical properties of the FCG scaffolds and in addition to
this, the scaffolds were capable of resisting cell-mediated contraction.

Table 1
Mechanical properties of FCG scaffolds treated with tropoelastin compared
against untreated samples on day 14.
Mechanical properties at day 14

Tropoelastin

Untreated

Compressive modulus (kPa)
Low strain tensile modulus (2–5%, kPa)
High strain tensile modulus (10–15%, kPa)
Ultimate tensile strength (kPa)
Strain to failure (%)

0.16 ± 0.02
1.6 ± 0.3
5.6 ± 0.08
64.7 ± 8.3
17.1 ± 1.3

0.19 ± 0.06
1.8 ± 0.4
6.6 ± 2
62 ± 19.3
15.9 ± 0.8

Fig. 9. Relative gene expression in FCG scaffolds. There was significant (A) ELN upregulation on day 3 of the experiment in samples treated with tropoelastin. No
significant expression changes in (B) EBP, (C) FBN1 and (D) LOX1 genes were measured. (^^) p < 0.01, when compared to untreated sample.
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Fig. 10. Mechanical testing (compressive and tensile) of FCG scaffolds. There was a slight decrease in both moduli by the end of the experiment. (A) Average stressstrain curves for compressive testing on day 14. (B) Stress-strain curves obtained during tensile testing on day 14. (C) Compressive modulus of FCG scaffolds treated
with tropoelastin, compared against untreated FCG scaffolds. By day 14, the average compressive moduli of treated samples was lower than the untreated samples.
(D) Tensile modulus at low and high strain of FCG scaffolds on day 14. There was a decrease in modulus at low strain of 11.05% and 15.79% at high stain in
tropoelastin-treated samples.

Fig. 11. Measurements of FCG scaffolds treated with tropoelastin showed no cell-mediated contraction. (A) There was no evidence of cell-mediated contraction in
FCG scaffolds treated with tropoelastin, when compared to untreated samples. (B) Size of treated and untreated FCG scaffolds after 14 days.

proliferation in these scaffolds.
After assessing the best day for the addition of tropoelastin on
hVSMCs seeded on glass slides, we could prove that ECM maturity af
fects the activation of elastogenesis. Waiting 10 days before adding
tropoelastin to hVSMCs (A10 samples), led to a significant increase in
the content of elastin and maturing elastic fibres than hVSMCs treated
with tropoelastin directly after seeding (A0 samples). Furthermore, A10
samples presented globules of elastin showing bead-like patterns on day
3 (Fig. 1E); this type of pattern has been shown by Kozel et al. to be
characteristic of the first stages of elastogenesis [52]. By day 7 (Fig. 1F),
the coacervation of tropoelastin was obvious and the ECM was saturated
in elastin. On day 14 the maturing elastic fibre alignment resembled

lamellar-like structure very similar to the ones of the tunica media in
arteries [5,53], and ventricularis layer in the leaflets of aortic heart
valves [54]. To prove this point, a directionality analysis was carried out
(Fig. 2C), showing that the maturing elastic fibres were aligned.
Although this was undoubtedly a feature of the hVSMCs used here, it
was nonetheless encouraging. From these results, it can be inferred that
the limiting factor in elastin deposition may be the content of ECMassociated proteins (fibulins [55,56], fibrillins [57], and microfibrillar
associate proteins [58]). We speculate that in the A0 samples, as tro
poelastin was added after cell seeding, the microfibrillar mesh in the
ECM was not fully formed, being unable to accommodate all the coac
ervated elastin, resulting in the loss of elastin during each growth
9
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medium change. This has also been observed by Kozel et al., showing
that elastin is unable to transform into an elastic fibre if there is no
presence of ECM [59]. Additionally, looking at the RT-qPCR results
(Fig. 4) all the elastin and maturing elastic fibres present in the ECM
were as a result of introducing the tropoelastin. We can assume this as
the levels of elastin (ELN) and LOX1 remained downregulated, whereas
Fibrillin-1 (FBN1) and EBP were upregulated. It is known that FBN1 is of
one of the elastic-fibre associated proteins in the microfibrillar mesh
responsible for signalling the assembly of mature elastic fibres in tissues
[57]. Therefore, the upregulation of FBN1 on day 7 shown in Fig. 4
makes sense, as there was a corresponding increase in the deposition of
maturing elastic fibres.
Having successfully used tropoelastin to induce elastogenesis in
hVSMCs on glass slides, we translated these results into a 3D model
using FCG scaffolds. After quantifying the amount of elastin deposited in
drop-loaded and media-loaded samples, we observed that the deposition
of elastin within the cell-seeded scaffolds occurred during the first 3 days
of this study and no significant changes were observed after the second
addition of tropoelastin on day 7 (Fig. 5). Additionally, while there was a
reduction in elastin content during the experiment, the rate of loss was
not significant. Furthermore, there were no significant differences in
elastin content between drop-loaded and media-loaded samples. On the
other hand, after visually assessing the scaffolds, we obtained twice the
surface area coverage of maturing elastic fibres by drop-loading tro
poelastin onto the cell-seeded FCG scaffolds, outperforming samples
where the tropoelastin was diluted in growth medium (media-loaded). It
is presumed that by drop-loading tropoelastin, the distribution of elastin
and elastic fibres on the scaffold surface was higher as the tropoelastin
solution was more concentrated when first in contact (for 10 min) with
the hVSMCs. Initially, the concentration of tropoelastin was 10 mg/ml
and when growth medium was added this reduced to 250 μg/ml in the
wells. However, by day 7 there was a reduction in elastin and no visible
maturing elastic fibres (Fig. 6B, F). This indicated that there was not
enough ECM secreted by the hVSMCs to allow deposition of elastin on
the surface of the FCG scaffolds. Interestingly, despite this, a second
addition of tropoelastin resulted in an increase in elastin and maturing
elastic fibre surface area coverage (Fig. 6C, G). By the end of the
experiment the surface of the FCG scaffolds presented maturing
branching elastic fibres along the scaffold pores, resembling the elastic
fibre architecture present in lungs [10]. Fibre alignment was corrobo
rated with a directionality analysis (Fig. 7C, D) and we saw that the
maturing elastic fibres in both drop-loaded and media-loaded samples
had no preferred orientation. These results imply that the hVSMCs had
by this point secreted enough ECM-associated proteins to support elastin
deposition and crosslinking on the surface of the FCG scaffold. To the
best of our knowledge this is the first study presenting the drop-loading
of tropoelastin on natural biomaterial cell-seeded scaffolds to induce
and control elastogenesis in vitro.
Having shown that controlled elastogenesis was possible by droploading tropoelastin, we carried out compressive and uniaxial tensile
testing on tropoelastin-treated FCG scaffolds and there were no detri
mental changes in mechanical properties. We could see that the
compressive modulus was lower in the samples treated with tropoelastin
(Fig. 10C) and in terms of tensile properties, when collagen and elastic
fibres began to straighten at low strain this resulted in a reduction of
tensile modulus (Fig. 10D). Similar results were observed at high strain,
presumably due to the elastic fibres transferring energy to the collagen
fibres to prevent overstretching [48]. Additionally, there was also an
increase in ultimate tensile strength and strain to failure (Table 1). It is
also noteworthy that after two weeks in vitro, FCG scaffolds were
dimensionally stable (Fig. 11B). This is an important attribute, as many
biomaterial constructs need to be capable of maintaining their shape
post-implantation.
Although the addition of tropoelastin resulted in an efficient way to
induce the formation of maturing elastic fibres in our FCG scaffolds, we
suggest that future work should focus on finding ways to further increase

the overall content of elastic fibres. Indeed, the use of supplements such
as microfibrillar associated protein 4 (MFAP4) [60], transforming
growth factor-β1 (TGF-β1) [61,62] and LOX1 [63] are also known to
induce a deposition of elastic fibres in fibroblasts and hVSMCs. Inter
estingly, Mithieux et al [31] obtained an increase in elastic fibre depo
sition using medium containing higher than usual ECM-associated
proteins. Recently, the use of macromolecular crowding techniques [64]
and cell co-culture with monocytes [65], have been used as alternatives
to enhance the deposition of ECM-associated proteins with promising
results. These techniques, in combination with dynamic conditioning,
using a bioreactor, might promote gene upregulation in cells, thus
improving elastic fibre deposition, ECM and cell proliferation [66–68] in
FCG scaffolds.
This FCG scaffold used here has applications in soft tissue recon
struction, as it combines fibrin’s wound-healing and remodelling prop
erties [37], the anti-calcification properties of GAGs [69], with collagen.
In this study, we have shown how tuneable amounts of elastic fibres can
be obtained by adding tropoelastin to stimulate elastogenesis [70]. As it
stands, the current mechanical properties of this construct makes it
suitable as a platform for skin [71] and lung alveolar wall regeneration
[72], and tunica media repair in blood vessels [36].
5. Conclusions
We have successfully demonstrated that elastogenesis can be acti
vated in the extracellular matrix (ECM) of cell-seeded scaffolds fabri
cated from fibrin, collagen and glycosaminoglycan (FCG) by adding
recombinant human tropoelastin. We have proven the importance of cell
density and having an ECM before adding tropoelastin for the deposition
of maturing elastic fibres in human vascular smooth muscle cells
(hVSMCs). It was observed that this technique allows the deposition of
elastin and formation of lamellar maturing elastic fibres, like the ones
found in skin, blood vessels and heart valves. Improved surface coverage
of maturing branched elastic fibres can be achieved by drop-loading
tropoelastin onto cell-seeded FCG scaffolds prior adding growth me
dium. Additionally, we could see the impact of elastic fibres in terms of
mechanical properties in the scaffolds. With these results, we have
established a natural biomaterial scaffold that can undergo controlled
elastogenesis on demand, suitable for tissue engineering applications.
CRediT authorship contribution statement
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